

Leukerbad——Maintaining Youthful Energy 洛伊克巴德——延续人类青春之光

—— Interview with Mr. Shao Luping, chairman of Leukerbad Rejuvenation Industry Group

—— 访洛伊克巴德年轻化产业集团董事长邵鲁平先生

□记者 李 莉

随着新一代大数据、大健康的加快渗透，洛伊克巴德年轻化产业集团将瑞士抗衰老养生、预防医疗、精准医疗及康复疗养的全链条生命资产管理体系以及阶梯式产品体系布局世界市场，通过大数据，推动创新，打造和推动了大健康项目的产业升级。

洛伊克巴德年轻化产业集团董事长邵鲁平先生介绍说：“洛伊克巴德年轻化产业集团成立于2007年，主要从事高净值人群的家族生命资产管理。集现代抗衰老产品的研发、生产、销售、服务于一体，致力于先端健康管理咨询、涉外医疗旅游服务、疾病预防、肿瘤筛查、健康数据采集分析、新型医疗保健产业的投融资等事务。洛伊克巴德于2016年全资收购了瑞士沃赛洛制药实验室(Serolab SA)，并于2018年完成了沃赛洛制药实验室(Serolab SA)和美集思实验室(Laboratoire Mergens SA)的合并。他们都是抗衰老产品和慢性病干预产品的权威研究机构，拥有国际药品生产质量管理规范GMP资格认证和瑞士药监局生产及发行许可。目前在中国有上海、深圳、西安3个服务中心和上海1家诊所，在大连、重庆、沈阳、武汉、南宁、苏州共有6个加盟网点，近千位高净值客户”。他说，随着“健康中国”建设上升至优先发展的国家战略层面，大健康产业已经成为中国经济转型的新引擎。2018年，中国大健康市场规模将达到4.4万亿元，至2022年大健康市场规模将达到7.4万亿元。洛伊克巴德在此背景下应运而生，将配合中国政府政策大力提倡“预防医学”。邵鲁平先生强调：“我们秉承‘延续人类青春之光’的企业宗旨和全球信息化医疗理念，洛伊克巴德年轻化产业集团整合全球高端医疗资源，建立精准医疗数据平台，提供全球知名医院的一站式服务。希望通过引进瑞士先端医疗理念和医疗技术来彻底改变国人对医疗行为的认知，让国人能更详细地了解世界发达国家的医疗方案。”

瑞士沃赛洛制药实验室位于瑞士弗里堡州雷马乌芬，是专业从



洛伊克巴德年轻化产业集团董事长邵鲁平先生
Mr. Shao Luping, chairman of Leukerbad Rejuvenation Industry Group

事药类产品研究、开发、生产、销售、进口、出口及代理业务的专业制药实验室。实验室从宏观、微观和应用三个维度探索验证出顺应自然的生命抗衰老修复医学体系，从生命表征深入到系统、器官、组织、细胞、基因，以生命起源与生命体健康生长的根本理论为科学基础，独创配伍配方方案，保护人体自动抗衰老，远离疾病。实验室创始人，让·托马斯(Jean Thomas)博士，1902年出生于法国，年轻时曾在中国、哥伦比亚、法国、越南等国进行医疗学习和研究交流。

1928年，让·托马斯博士开始了对新型多克隆疗法探索。1958年，他定居瑞士，将自己数十年研究的多克隆生物疗法成果首先运用于Serocytol系列栓剂产品的研发制造，该系列药品对多种慢性病有明显治疗效果。1967年开始，让·托马斯博士及其后继者每两年



瑞士沃赛洛制药实验室外景



上海服务中心外景

定期组织医生和医疗科研人员进行学术交流，成立了“血清细胞学国际专业研究委员会”。从此不断强化了实验室药品的医学科学基础。实验室历经数十年研发，不仅生产了高品质多克隆抗体生物制剂产品，而且自主研发了创新型细胞4DH滴剂，从而迅速在欧洲上层社会中声名鹊起。

瑞士沃赛洛制药实验室的赛尔西都系列栓剂一直是广受欢迎的明星产品。栓剂的特异性免疫球蛋白，即特异性抗体，可直接作用于它相应器官(靶器官)或组织。它们将对人体器官产生调节和修复作用。栓剂都是直肠给药，通过直肠黏膜的迅速吸收进入大循环，因而起效很快，对各类慢性病的临床效果非常显著。瑞士沃赛洛制药实验室60年来临床实验表明，这种栓剂疗法温和、稳定、无副作用，非常适合幼儿、老年人及体弱病人。

创新是洛伊克巴德的重要引擎。邵鲁平结合国家的发展规划和战略，把加强创新能力摆在更加突出的位置，加强关键核心技术攻关，加强科技成果产业化，提高关键环节和重点领域的创新能力，走创新驱动的发展之路。采用大数据的思维方法，对传统的研发方法进行本质上的改变，利用多年的研发经验和对产品的理解确定产品的研发战略，提前几年预测产品的推出期，并及时更新换代，形成一个以客户为导向的研发平台，使得洛伊克巴德迈入了历史新阶段。瑞士沃赛洛制药实验室研制的多克隆抗体生物疗法，是利用特异性免疫球蛋白输入人体，从而被动性获得免疫力的治疗方法。先天免疫力是可以自然获得的，但抗病能力因人而异，且伴随着年龄，生活条件和饮食卫生发生变化。而多克隆抗体疗法可以通过人工注射特异性抗体，获得自身免疫力，以预防疾病。实验室产品生产方法来源于60年前让·托马斯博士的研究成果。实验室拥有多克隆疗法药品(补充类药品)、顺势疗法药品、保健食品、植物疗法药品等四大主导系列药品。实验室产品符合瑞士药典规范，生产包装全部在瑞士完成，经Swissmedic(瑞士药监局)认证其生产过程符合国际GMP规范。如今的瑞士沃赛洛制药实验室，通过致力于研究功能性疾病更好的治疗方案，并研发提供传统治疗的补充疗法，现已拥有1000多种人体平衡疗法药品的生产许可(滴剂、针剂、栓剂等)，依托瑞士顶尖的生物制药技术和强大的基因、病理数据库，针对人体九大系统，独创了一整套完善的生命活化方案，可对80余种常见的慢性病症实现定制化精准配伍，实现了慢性病治疗及人体免疫平衡修复的突破式发

展。

邵鲁平的每一步棋，都能让洛伊克巴德登上一个新的台阶，都是一次质的飞跃。2015年6月26日，洛伊克巴德年轻化产业集团“生命银行全球合伙人招募峰会”圆满举行。2016年4月22日，洛伊克巴德年轻化产业集团和瑞士沃赛洛制药实验室参加第三届中国国际医疗旅游博览会。2017年2月，保险第三方服务公司AMC(中保通医疗管理有限公司)正式成立，成为洛伊克巴德的战略伙伴，著名经济学家金岩石老师和吴克忠老师也先后成为洛伊克巴德的战略投资人。2017年7月8日，洛伊克巴德邵鲁平董事长被邀出席汉堡G20峰会一带一路德中合作论坛，并发表了“一带一路背景下中国大健康产业的机遇和挑战”的主旨演讲。2017年7月6日至12日，CCTV发现之旅《魅力中国》栏目开启“发现欧洲之旅·中外文化交流大型系列专题展播活动”走进瑞士，实地探访瑞士沃赛洛制药实验室。2017年10月26日，健康中国2030大健康产业论坛暨洛伊克巴德成立10周年盛典在上海西郊宾馆隆重召开，原卫生部党组书记、部长，现任中国健康管理协会总顾问高强先生作为论坛启幕嘉宾发表了重要讲话。2018年2月，由瑞士沃赛洛制药实验室股份有限公司发起的生命链事业部成立，并于同年5月完成了与瑞士美集思实验室的合并。

21世纪是人类追求健康的新时代，“一带一路”为推动健康医疗的开放、交流和融合提供了更大的契机和平台。作为一家医疗科技企业，洛伊克巴德十多年来一直努力与欧洲高端医疗体系达成合作。邵鲁平作为企业的创始人之一，运用狼性制度，柔性关怀，多维度管理，使得跟随他的瑞士沃赛洛制药实验室雇员及百位世界一线生物科研专家始终坚守在探索生命科学奥秘的第一线，专注于抗衰老和环境影响产生的各种疾病。邵鲁平本人不仅是洛伊克巴德年轻化产业集团董事长、瑞士沃赛洛制药实验室的董事长，也是中国民族卫生协会抗衰老专业委员会主任。瑞士沃赛洛制药实验室拥有领先的医疗技术、顶尖的专家团队、优质的生物制剂，但邵董事长并不满足于现状，不断地将中国历史悠久的中医中草药文化融入其中，完美结合了东、西方力量，进行了中西医合并，采用科学配伍，达到精准干预治疗。下一步，邵鲁平要打造“东方洛伊克巴德抗衰老健康小镇”，建设中国特色小镇医疗经济的“国际健康养生集群”，以此来实现“延续人类青春之光”的愿景！




小分子维生素喷雾系列

Mr. Shao Luping, chairman of Leukerbad Rejuvenation Industry Group, said that the Group was founded in 2007 and it specializes in family health care management for high income people. Engaging in R&D, production, sale and services of modern anti-aging products, it devotes to advanced health management consultancy, medical tourism services, diseases preventing, tumor scanning, health data collecting & analyzing, investment & financing of new health care industry and others. Leukerbad acquired 100 interest of Serolab SA, Switzerland in 2016 and Serolab SA incorporated with Labotatoire Mergens SA in 2018. With GMP and Swissmedic certification for production and sale, these two laboratories are research authorities for anti-aging products and intervention products for chronic diseases. Currently in China, there are 3 service centers respectively in Shanghai, Shenzhen, Xi'an, 1 clinic in Shanghai, 6 franchisees respectively in Dalian, Chongqing, Shenyang, Wuhan, Nanning and Suzhou, nearly 1000 high income clients as well. Mr. Shao Luping remarked that, comprehensive health industry has been a new engine for China economic transformation, as building a healthy China is becoming a priority in national strategy. The size of Chinese comprehensive health market will reach 4.4 trillion RMB in 2018, while 7.4 trillion RMB in 2022. Leukerbad comes into being against this background and promotes prevention medicine responding to the policy of Chinese government. Mr. Shao Luping stressed out that, upholding the company mission of Maintaining Youthful Energy and concept of global information-based medicine, Leukerbad Rejuvenation Industry Group provides one-stop services of well-known global hospitals with integration of high end global medical resources and establishment of precision medical data platform. It is hoped to alter our people's perceptions of medical acts and let them have more detailed information on medical projects from developed countries by introducing advanced Swiss medical concept and technology.

A photograph showing a variety of pharmaceutical products. In the background, there are several boxes of different colors (orange, green, blue, pink, yellow) with labels such as "As-Visculo-Rhecto", "OFR", "SRE", "Nervex", "Fole", "Emorictaires", "Neuro-anesthésique", and "CEA". In the foreground, three white, rectangular tablets are displayed, each labeled "MORPHINE HCL".

抗体栓剂



laboratory specializes in research, development, production, sale, importation and exportation of medicines and agent services. On the basis of three dimensions including macro and micro levels and application, it established an anti-aging and rehabilitative medical system complying with nature after discovery and verification. From surface features of life to systems, organs, tissues, cells and gens, and on the scientific basis on the elementary theory about the origin of life and normal growth of the body, original compatibilities of medicines are created to automatically protect human body from aging and diseases. The founder of the laboratory, Dr. Jean Thomas, was born in 1902 in France. As a young man, he studied medicine and conducted research interchanges in China, Columbia, France and Vietnam. In 1928, Mr. Jean Thomas started his research on a new type of therapy based on polyclonal antibody. Following decades of research, Jean Thomas achieved the result in biotherapy. In 1958, the achievements were first employed in research, development and production of Serocytol product range after Jean Thomas's settlement in Switzerland. The product range is significantly effective in treating chronic diseases. Started in 1967, Dr. Jean Thomas and his followers organized doctors and medical researchers to engage in academic exchanges every two years and the Internationally Professional Research Commission on Serum and Cytology was established. Thus the scientific foundations in medicine were progressively strengthened. After decades of independent research and development, the laboratory produces not only polyclonal antibody based biological preparations of high quality, but innovative 4DH drops. Since then, it has been gained great reputations immediately in European upper class.

Innovation has been a crucial engine for Leukerbad. In response to national development planning and strategy, Shao Luping resumes a development path driven by innovation. He gives a more prominent place for strengthening innovation capacity, finds solutions to major technical difficulties, strengthens the industrialization of scientific and technological achievements and enhances innovative capacity in key aspects and areas. A perspective on big data is adopted to fundamentally change the traditional R&D method. With many years of R&D experience and understanding of products, a strategy for product research and development is finalized. Thus the product launching can be predicted several years in advance, and products are upgraded timely, establishing a client-oriented R&D platform. A new phase in Leukerbad's history starts. The polyclonal antibody based biological therapy, developed by Serolab SA, is the therapy making human body immune after the specific immunoglobulin entering into it. Human body was born to have immunity. However, its disease resistance is different. And it alters in response to age, living condition and food hygiene. While the polyclonal antibody based therapy makes the body autoimmune by injecting specific antibody, so as to prevent diseases. The production method of Serolab SA originates in Jean Thomas's research achievements 60 years ago. There are 4 major product ranges in Serolab, including polyclonal antibody medicines (complementary medicines), homeopathic medicines, health care products and phytotherapeutic products. The products from Serolab



抗体针剂

Every initiative Shao Luping takes leads to a new level and a qualitative leap. Global Partner Recruitment Summit of Leukerbad Rejuvenation Industry Group was successfully held



On 26th June, 2015, Leukerbad Rejuvenation Industry Group and Serolab SA, Switzerland took part in the 3rd China International Medical Tourism Fair on 22nd April, 2016. After formal establishment in February 2017, AMC, the third-party service provider in insurance (Zhongbaotong Medical Management Co., Ltd.) became strategic partner to Leukerbad. Renowned economists Mr. Jin Yanshi and Mr. Wu Kezhong successively became strategic partners to Leukerbad. On 8th July, 2017, Mr. Shao Luping, chairman of Leukerbad, was invited to attend G20 Summit One Belt One Road German-Chinese Cooperation Forum, and delivered speech Opportunities and Challenges of China Comprehensive Health Industry under One Belt One Road. From 6th to 12th of July 2017, the working group from Charming China of OUTLOOK, CCTV went to Switzerland and paid a visit to Serolab SA as a range of thematic broadcast exhibition events Discovery of Europe · Chinese-foreign Exchanges in Culture were carried out. Healthy China 2030 Comprehensive Health Industry Forum & Leukerbad 10th Anniversary Celebration was grandly held in Xijiao State Guest Hotel. As a curtain-raiser for the forum, Mr. Gao Qiang, former secretary and minister of Ministry of Health, incumbent chief adviser of China Health Management Association, delivered an important speech. Business sector for Life Chain initiated by Serolab SA was set up in February, 2018. Serolab SA and Laboratoire Mergens SA were merged in the same year.

21st century has been a new era for pursuit of health. One Belt One Road Initiative presents more opportunities and platforms for openness, exchanges and integration of medicine. As a medical technology company, Leukerbad has been endeavored to enter into cooperation with top European medical systems for more than 10 years. Shao Luping, one of the founders of the company, employs multidimensional managements, including system with wolf spirit and cares for human beings, making his followers, the employees from Serolab SA, and 100 most important scientific research professionals in biology work in responsible position for discovering the mysteries of life sciences and concentrate on various diseases affected by aging and environment. Shao Luping himself is not only the chairman of Leukerbad Rejuvenation Industry Group, chairman of Serolab SA, Switzerland, but the director of Professional Anti-aging Committee, China National Health Association. Though Serolab SA possesses advanced biotechnology, top team of experts and biological preparations of high quality, Shao Luping is not satisfied with maintaining this status quo. Accordingly, he continuously integrates the longstanding traditional Chinese medicine and Chinese herbal medicine into western medicine, which reaches a harmonious blend of advantages between the East and the West. As a result, science-based compatibilities of medicine are applied for precise intervention and treatment. The next step will be the establishment of Eastern Leukerbad Anti-aging and Healthy Town and International Health Maintaining Group, the Chinese-style town focusing on medical economics, to realize the vision of Maintaining Youthful Energy.